|
Research Management and Support
|
RMS ES 2017
|
$326,124,631
|
$1,816,148
|
N/A
|
National Institutes of Health
|
|
Modeling bladder cancer pathogenesis and tumor evolution
|
1P01CA221757-01A1
|
$1,765,498
|
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S1
|
$120,000
|
$2,400
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S2
|
$60,000
|
$1,200
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S3
|
$118,652
|
$2,373
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S4
|
$199,541
|
$3,991
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-43
|
$3,792,720
|
$75,854
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
A biomarker-driven strategy to guide the use of radiotherapy in non-small cell lung cancer
|
1R37CA222294-01A1
|
$366,000
|
|
ABAZEED, MOHAMED
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Novel platform linking cancer-specific glycosylation with cell signaling outcomes
|
1R21CA229044-01
|
$225,250
|
$112,625
|
ABBOTT, KAREN
|
UNIV OF ARKANSAS FOR MED SCIS
|
|
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
|
3UM1CA186704-04S1
|
$170,500
|
|
ABBRUZZESE, JAMES
|
DUKE UNIVERSITY
|
|
Identifying molecular drivers of tumor heterogeneity in pancreatic cancer
|
1F31CA224792-01A1
|
$36,672
|
|
ADAMS, CHRISTINA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Discovery and Characterization of Mutations in Breast and Ovarian Cancers
|
5R50CA211280-02
|
$215,047
|
$107,524
|
ADAMSON, AARON
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
AFRICAN FEMALE BREAST CANCER EPIDERMIOLOGY (AFBRECANE) STUDY
|
5U01HG009784-02
|
$85,000
|
|
ADEBAMOWO, CLEMENT
|
INSTITUTE OF HUMAN VIROLOGY
|
|
University of North Carolina Womens Interagency HIV Study UNC WIHS
|
3U01AI103390-05S1
|
$60,652
|
|
ADIMORA, ADAORA
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Identifying the Drivers and Targeting Chemo Resistance in Ovarian Cancer
|
1R01CA211648-01A1
|
$429,211
|
$429,211
|
ADLI, MAZHAR
|
UNIVERSITY OF VIRGINIA
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-07
|
$1,414,315
|
$70,716
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
|
1R01CA236615-01
|
$392,764
|
|
ADUSUMILLI, PRASAD
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
5R03CA212798-02
|
$74,250
|
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Leveraging polyamine metabolic stress as a novel therapy for prostate cancer
|
4K00CA212455-03
|
$69,749
|
|
AFFRONTI, HAYLEY
|
UNIVERSITY OF PENNSYLVANIA
|
|
Genetics of Graft-versus-Host Disease
|
1R01CA231141-01
|
$265,229
|
|
AFSHAR-KHARGHAN, VAHID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Platelets promote growth of ovarian cancer
|
5R01CA177909-05
|
$332,000
|
$332,000
|
AFSHAR-KHARGHAN, VAHID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
3R01CA195708-05S1
|
$94,087
|
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
5R01CA195708-05
|
$382,616
|
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Policy- and Provider-Level Determinants of Human Papillomavirus Vaccination Disparities Among Young U.S. Women
|
1K01CA234226-01
|
$158,403
|
|
AGENOR, MADINA
|
TUFTS UNIVERSITY MEDFORD
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-03S1
|
$154,939
|
$3,099
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
$2,907
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-04
|
$737,200
|
$14,744
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Modeling and druggable-genome screening of glioblastoma invasion using regional biopsy-guided biomaterials systems
|
1R01CA227136-01A1
|
$454,956
|
|
AGHI, MANISH
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
3U54CA137788-10S1
|
$54,859
|
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
3U54CA137788-10S2
|
$188,884
|
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy
|
1R43CA228813-01A1
|
$300,000
|
|
AHMED, HAFIZ
|
GLYCOMANTRA, INC.
|
|
Nucleotide Metabolism in Senescence and Platinum Resistance of Ovarian Cancer
|
4R00CA194309-03
|
$249,000
|
$249,000
|
AIRD, KATHERINE
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
Dr. Keiko Akagi, A Bioinformatics Specialist in Cancer Genomics Research at OSU Comprehensive Cancer Center
|
5R50CA211533-03
|
$122,475
|
|
AKAGI, KEIKO
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Metabolic Syndrome and Epigenetic Markers of Breast Cancer in Nigerian Women
|
5K01TW010271-03
|
$134,531
|
|
AKINYEMIJU, TOMI
|
UNIVERSITY OF KENTUCKY
|
|
Title: Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA in Combination with Immune Checkpoint Blockade
|
1R43CA228721-01
|
$299,607
|
|
AKPORIAYE, EMMANUEL
|
VEANA THERAPEUTICS, LLC
|
|
Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers
|
1P01CA217805-01A1
|
$2,105,511
|
|
ALBELDA, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-04
|
$1,367,856
|
$27,357
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
Chemically produced neural progenitors as a delivery vehicle for anti-glioma therapy
|
1R43CA221490-01A1
|
$300,000
|
|
ALEXANIAN, ARSHAK
|
CELL REPROGRAMMING AND THERAPEUTICS, LLC
|
|
Chemically produced neural progenitors loaded with ferumoxide-protamine sulfate complex for visualization of gliomas
|
1R43CA228726-01A1
|
$300,000
|
|
ALEXANIAN, ARSHAK
|
CELL REPROGRAMMING AND THERAPEUTICS, LLC
|
|
Commercialization of a proprietary Ga-68 PSMA-targeted drug for PET imaging in recurrent prostate cancer
|
1R44CA233140-01
|
$299,412
|
|
ALEXOFF, DAVID
|
FIVE ELEVEN PHARMA, INC.
|
|
Tumor Embolization Using A Novel Catheter With Integrated Flow Regulation
|
2R44CA192428-02A1
|
$893,847
|
|
ALLEN, MICHAEL
|
EMBOLX, INC.
|
|
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas
|
7R01CA182076-05
|
$339,622
|
|
ALLEN, PETER
|
DUKE UNIVERSITY
|
|
Targeting defective DNA repair for the prevention of BRCA1-associated cancers
|
5K22CA181550-03
|
$162,000
|
$81,000
|
ALLI, ELIZABETH
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
Oncohistones: Role of Histone H3 Mutations in the Oncogenesis of Pediatric Cancers
|
5P01CA196539-04
|
$1,855,117
|
|
ALLIS, CHARLES
|
ROCKEFELLER UNIVERSITY
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics
|
5U01CA202144-03
|
$704,509
|
$352,255
|
ALTER, ORLY
|
UNIVERSITY OF UTAH
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-48S1
|
$142,498
|
$15,675
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
$18,525
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
Total relevant funding to Ovarian Cancer for this search: $135,146,206
|